{"id":18257,"date":"2014-11-14T13:37:03","date_gmt":"2014-11-14T13:37:03","guid":{"rendered":"https:\/\/www.editage.com\/insights\/research\/drug-resistant-cancer-responds-to-personalized-drug-combinations\/"},"modified":"2025-09-19T16:06:24","modified_gmt":"2025-09-19T10:36:24","slug":"drug-resistant-cancer-responds-to-personalized-drug-combinations","status":"publish","type":"research","link":"https:\/\/www.editage.com\/insights\/drug-resistant-cancer-responds-to-personalized-drug-combinations","title":{"rendered":"Drug-resistant cancer responds to personalized drug combinations"},"content":{"rendered":"

Cancer researcher and physician Jeffrey Engelman<\/a> of the Massachusetts General Hospital in Boston has found a promising way of treating drug-resistant cancer by growing patients\u2019 tumor cells and testing various drug combinations on them to find a way of effective treatment. Engelman and his colleagues devised a way to culture lung cancer cells from patient samples and then test them against a battery of 76 different drugs, and they got encouraging results. According to the researcher, this cell-culture model could make personalized drug screening faster as compared to using a mouse model. However, the team reported that they got unexpected results during their study; for example, cell samples that were resistant to therapies targeting a protein called ALK were felled by different drugs that inhibited another protein called SRC. Further research is required before this treatment can be used for patients.<\/span><\/span><\/p>\n

Read more in Nature<\/a><\/em>. \u00a0 \u00a0<\/span><\/span><\/p>\n","protected":false},"author":8,"featured_media":33313,"template":"","meta":{"_acf_changed":false,"inline_featured_image":false},"new_tags":[],"series":[],"subject":[2976,2974,2975],"class_list":["post-18257","research","type-research","status-publish","has-post-thumbnail","hentry","subject-and-molecular-biology","subject-biochemistry","subject-genetics"],"acf":[],"yoast_head":"\nDrug-resistant cancer responds to personalized drug combinations | Editage Insights<\/title>\n<meta name=\"description\" content=\"Cancer researcher and physician Jeffrey Engelman of the Massachusetts General Hospital in Boston has found a promising way of treating drug-resistant cancer by growing patients\u2019 tumor cells and testing various drug combinations on them to find a way of effective treatment. Read on to find out more.\u00a0\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.editage.com\/insights\/drug-resistant-cancer-responds-to-personalized-drug-combinations\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Drug-resistant cancer responds to personalized drug combinations | Editage Insights\" \/>\n<meta property=\"og:description\" content=\"Cancer researcher and physician Jeffrey Engelman of the Massachusetts General Hospital in Boston has found a promising way of treating drug-resistant cancer by growing patients\u2019 tumor cells and testing various drug combinations on them to find a way of effective treatment. Read on to find out more.\u00a0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.editage.com\/insights\/drug-resistant-cancer-responds-to-personalized-drug-combinations\" \/>\n<meta property=\"og:site_name\" content=\"Editage Insights\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/Editage\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-19T10:36:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.editage.com\/insights\/wp-content\/uploads\/2025\/06\/editage-insights-generic-banner.png\" \/>\n\t<meta property=\"og:image:width\" content=\"870\" \/>\n\t<meta property=\"og:image:height\" content=\"446\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@Editage\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.editage.com\/insights\/drug-resistant-cancer-responds-to-personalized-drug-combinations\",\"url\":\"https:\/\/www.editage.com\/insights\/drug-resistant-cancer-responds-to-personalized-drug-combinations\",\"name\":\"Drug-resistant cancer responds to personalized drug combinations | Editage Insights\",\"isPartOf\":{\"@id\":\"https:\/\/www.editage.com\/insights\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.editage.com\/insights\/drug-resistant-cancer-responds-to-personalized-drug-combinations#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.editage.com\/insights\/drug-resistant-cancer-responds-to-personalized-drug-combinations#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.editage.com\/insights\/wp-content\/uploads\/2025\/02\/editage-insights-generic-banner_298.webp\",\"datePublished\":\"2014-11-14T13:37:03+00:00\",\"dateModified\":\"2025-09-19T10:36:24+00:00\",\"description\":\"Cancer researcher and physician Jeffrey Engelman of the Massachusetts General Hospital in Boston has found a promising way of treating drug-resistant cancer by growing patients\u2019 tumor cells and testing various drug combinations on them to find a way of effective treatment. Read on to find out more.\u00a0\",\"breadcrumb\":{\"@id\":\"https:\/\/www.editage.com\/insights\/drug-resistant-cancer-responds-to-personalized-drug-combinations#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.editage.com\/insights\/drug-resistant-cancer-responds-to-personalized-drug-combinations\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.editage.com\/insights\/drug-resistant-cancer-responds-to-personalized-drug-combinations#primaryimage\",\"url\":\"https:\/\/www.editage.com\/insights\/wp-content\/uploads\/2025\/02\/editage-insights-generic-banner_298.webp\",\"contentUrl\":\"https:\/\/www.editage.com\/insights\/wp-content\/uploads\/2025\/02\/editage-insights-generic-banner_298.webp\",\"width\":656,\"height\":336},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.editage.com\/insights\/drug-resistant-cancer-responds-to-personalized-drug-combinations#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.editage.com\/insights\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Researchs\",\"item\":\"https:\/\/www.editage.com\/insights\/research\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Drug-resistant cancer responds to personalized drug combinations\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.editage.com\/insights\/#website\",\"url\":\"https:\/\/www.editage.com\/insights\/\",\"name\":\"Editage Insights\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.editage.com\/insights\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.editage.com\/insights\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.editage.com\/insights\/#organization\",\"name\":\"Editage Insights\",\"url\":\"https:\/\/www.editage.com\/insights\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.editage.com\/insights\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.editage.com\/insights\/wp-content\/uploads\/2024\/09\/editage-insights-logo-1-scaled.webp\",\"contentUrl\":\"https:\/\/www.editage.com\/insights\/wp-content\/uploads\/2024\/09\/editage-insights-logo-1-scaled.webp\",\"width\":2560,\"height\":324,\"caption\":\"Editage Insights\"},\"image\":{\"@id\":\"https:\/\/www.editage.com\/insights\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Editage\",\"https:\/\/x.com\/Editage\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Drug-resistant cancer responds to personalized drug combinations | Editage Insights","description":"Cancer researcher and physician Jeffrey Engelman of the Massachusetts General Hospital in Boston has found a promising way of treating drug-resistant cancer by growing patients\u2019 tumor cells and testing various drug combinations on them to find a way of effective treatment. Read on to find out more.\u00a0","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.editage.com\/insights\/drug-resistant-cancer-responds-to-personalized-drug-combinations","og_locale":"en_US","og_type":"article","og_title":"Drug-resistant cancer responds to personalized drug combinations | Editage Insights","og_description":"Cancer researcher and physician Jeffrey Engelman of the Massachusetts General Hospital in Boston has found a promising way of treating drug-resistant cancer by growing patients\u2019 tumor cells and testing various drug combinations on them to find a way of effective treatment. Read on to find out more.\u00a0","og_url":"https:\/\/www.editage.com\/insights\/drug-resistant-cancer-responds-to-personalized-drug-combinations","og_site_name":"Editage Insights","article_publisher":"https:\/\/www.facebook.com\/Editage","article_modified_time":"2025-09-19T10:36:24+00:00","og_image":[{"width":870,"height":446,"url":"https:\/\/www.editage.com\/insights\/wp-content\/uploads\/2025\/06\/editage-insights-generic-banner.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@Editage","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.editage.com\/insights\/drug-resistant-cancer-responds-to-personalized-drug-combinations","url":"https:\/\/www.editage.com\/insights\/drug-resistant-cancer-responds-to-personalized-drug-combinations","name":"Drug-resistant cancer responds to personalized drug combinations | Editage Insights","isPartOf":{"@id":"https:\/\/www.editage.com\/insights\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.editage.com\/insights\/drug-resistant-cancer-responds-to-personalized-drug-combinations#primaryimage"},"image":{"@id":"https:\/\/www.editage.com\/insights\/drug-resistant-cancer-responds-to-personalized-drug-combinations#primaryimage"},"thumbnailUrl":"https:\/\/www.editage.com\/insights\/wp-content\/uploads\/2025\/02\/editage-insights-generic-banner_298.webp","datePublished":"2014-11-14T13:37:03+00:00","dateModified":"2025-09-19T10:36:24+00:00","description":"Cancer researcher and physician Jeffrey Engelman of the Massachusetts General Hospital in Boston has found a promising way of treating drug-resistant cancer by growing patients\u2019 tumor cells and testing various drug combinations on them to find a way of effective treatment. Read on to find out more.\u00a0","breadcrumb":{"@id":"https:\/\/www.editage.com\/insights\/drug-resistant-cancer-responds-to-personalized-drug-combinations#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.editage.com\/insights\/drug-resistant-cancer-responds-to-personalized-drug-combinations"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.editage.com\/insights\/drug-resistant-cancer-responds-to-personalized-drug-combinations#primaryimage","url":"https:\/\/www.editage.com\/insights\/wp-content\/uploads\/2025\/02\/editage-insights-generic-banner_298.webp","contentUrl":"https:\/\/www.editage.com\/insights\/wp-content\/uploads\/2025\/02\/editage-insights-generic-banner_298.webp","width":656,"height":336},{"@type":"BreadcrumbList","@id":"https:\/\/www.editage.com\/insights\/drug-resistant-cancer-responds-to-personalized-drug-combinations#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.editage.com\/insights\/"},{"@type":"ListItem","position":2,"name":"Researchs","item":"https:\/\/www.editage.com\/insights\/research"},{"@type":"ListItem","position":3,"name":"Drug-resistant cancer responds to personalized drug combinations"}]},{"@type":"WebSite","@id":"https:\/\/www.editage.com\/insights\/#website","url":"https:\/\/www.editage.com\/insights\/","name":"Editage Insights","description":"","publisher":{"@id":"https:\/\/www.editage.com\/insights\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.editage.com\/insights\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.editage.com\/insights\/#organization","name":"Editage Insights","url":"https:\/\/www.editage.com\/insights\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.editage.com\/insights\/#\/schema\/logo\/image\/","url":"https:\/\/www.editage.com\/insights\/wp-content\/uploads\/2024\/09\/editage-insights-logo-1-scaled.webp","contentUrl":"https:\/\/www.editage.com\/insights\/wp-content\/uploads\/2024\/09\/editage-insights-logo-1-scaled.webp","width":2560,"height":324,"caption":"Editage Insights"},"image":{"@id":"https:\/\/www.editage.com\/insights\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Editage","https:\/\/x.com\/Editage"]}]}},"_links":{"self":[{"href":"https:\/\/www.editage.com\/insights\/wp-json\/wp\/v2\/research\/18257","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.editage.com\/insights\/wp-json\/wp\/v2\/research"}],"about":[{"href":"https:\/\/www.editage.com\/insights\/wp-json\/wp\/v2\/types\/research"}],"author":[{"embeddable":true,"href":"https:\/\/www.editage.com\/insights\/wp-json\/wp\/v2\/users\/8"}],"version-history":[{"count":0,"href":"https:\/\/www.editage.com\/insights\/wp-json\/wp\/v2\/research\/18257\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.editage.com\/insights\/wp-json\/wp\/v2\/media\/33313"}],"wp:attachment":[{"href":"https:\/\/www.editage.com\/insights\/wp-json\/wp\/v2\/media?parent=18257"}],"wp:term":[{"taxonomy":"new_tags","embeddable":true,"href":"https:\/\/www.editage.com\/insights\/wp-json\/wp\/v2\/new_tags?post=18257"},{"taxonomy":"series","embeddable":true,"href":"https:\/\/www.editage.com\/insights\/wp-json\/wp\/v2\/series?post=18257"},{"taxonomy":"subject","embeddable":true,"href":"https:\/\/www.editage.com\/insights\/wp-json\/wp\/v2\/subject?post=18257"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}